As a highly potent, natural anticoagulant, heparin is well known as an antithrombotic agent, and it has been shown to inhibit smooth muscle cell proliferation. INTERGARD Heparin grafts incorporate ...

are due to its lower affinity for heparin-binding proteins and endothelial cells, shorter fractionated heparin chain (which allows for better bioavailability), and unsaturable renal elimination.

After more than 70 years of effective clinical use, heparin remains the most common anticoagulant in use and one of the most commonly prescribed drugs to hospitalized patients. However ...

Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...

Some of Sharfstein’s current work with her lab at UAlbany includes developing heparin, a blood thinner, from hamster ovary cells. Sharfstein is also working with DeepSeq.AI and its CEO Andrew ...

Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...

Aplagon announces EUR 7 million financing to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2A trials: Helsinki Tuesday, February 4, 2025, 16:00 Hrs [IS ...